File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Treatment outcome with DAAs in a multinational cohort of 11,099 hepatitis C (CHC) patients with genotypes 1, 2, 3, 4 and 6: A REAL-C study

TitleTreatment outcome with DAAs in a multinational cohort of 11,099 hepatitis C (CHC) patients with genotypes 1, 2, 3, 4 and 6: A REAL-C study
Authors
Issue Date2021
PublisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072
Citation
The 30th Annual Conference of the Asian Pacific for The Study of Liver (APASL), Hybrid Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S60-S61 How to Cite?
AbstractObjectives: The Western Pacific is a large region but few studies have examined the real-world outcomes of DAAs in a multinational study with diverse HCV genotypes (GT). This REAL-C study (real-world evidence from the Asia Pacific Rim Liver Consortium for HCV) will characterize CHC patients treated with DAAs in routine practice. Methods: We analyzed 11,099 CHC patients from 51 REAL-C clinical sites from Mainland China, Hong Kong, Taiwan, Korea, Japan, and Singapore. The primary outcome was SVR12. Results: The cohort had mean age of 64.0, 44.8% male, 24.2% Chinese (10.0% Mainland China, 1.2% HK, 13.0% Taiwan), 7.5% Korean, 68.1% Japanese, 32.6% with cirrhosis, 9.1% HCC, and 27.0% treatment-experienced (TE: 23.2% interferon, 3.8% DAA). The largest group was GT1 (7837 [70.6%]: 642 1a, 7195 1b), then GT2 (2945 [26.5%]: 1761 2a, 1184 2b), GT3 (211: 70 3a, 126 3b, 11 others), GT6 (91), GT4 (5), and mixed (10). DAA use was also diverse: 3349 (30.2%) SOF/LDF ± RBV, 2437 (22.0%) SOF + RBV, 2251 (20.3%) DCV + ASV, 1270 (11.4%) 2D/3D ± RBV, 633 (5.7%) GLE/PIB, 623 (5.6%) SOF/VEL ± RBV, and others. Overall SVR12 was 96.2% (10,674/11099). By cirrhosis and prior treatment, SVR12 was > 96% for all groups, except GT1 cirrhosis/TE (93.4%, 759/813), GT2 cirrhosis/TE (89.0%, 146/164 [144 with SOF + RBV]), GT3 cirrhosis/TE (88.9%, 8/9), and GT6 no cirrhosis/TE (93.3%, 14/15). There was no treatment-related SAE. Conclusion: In this diverse cohort of Asian patients with genotypes 1, 2, 3, 4 and 6, the overall cure rate was 96.2%, despite large numbers of cirrhosis, HCC, prior treatment failure, and older DAA use.
DescriptionPoster presentation - Hepatitis C: no. I-26
Persistent Identifierhttp://hdl.handle.net/10722/308327
ISSN
2021 Impact Factor: 9.029
2020 SCImago Journal Rankings: 1.304

 

DC FieldValueLanguage
dc.contributor.authorJi, FP-
dc.contributor.authorOgawa, E-
dc.contributor.authorHuang, CF-
dc.contributor.authorToyoda, H-
dc.contributor.authorJun, DW-
dc.contributor.authorIio, E-
dc.contributor.authorNozaki, A-
dc.contributor.authorAtsukawa, M-
dc.contributor.authorHsu, YC-
dc.contributor.authorYokohama, K-
dc.contributor.authorAsai, A-
dc.contributor.authorUojima, H-
dc.contributor.authorWatanabe, T-
dc.contributor.authorTseng, CH-
dc.contributor.authorHaga, H-
dc.contributor.authorEnomoto, M-
dc.contributor.authorAbe, H-
dc.contributor.authorYasuda, S-
dc.contributor.authorLiu, L-
dc.contributor.authorLee, DH-
dc.contributor.authorTakahashi, H-
dc.contributor.authorIshikawa, T-
dc.contributor.authorLi, J-
dc.contributor.authorLiang, J-
dc.contributor.authorYoon, EL-
dc.contributor.authorAhn, SB-
dc.contributor.authorLi, J-
dc.contributor.authorLiu, J-
dc.contributor.authorSenoh, T-
dc.contributor.authorWang, X-
dc.contributor.authorLam, CPM-
dc.contributor.authorHuang, R-
dc.contributor.authorZhang, J-
dc.contributor.authorWong, G-
dc.contributor.authorCai, D-
dc.contributor.authorWang, Q-
dc.contributor.authorZhao, C-
dc.contributor.authorHuang, DQ-
dc.contributor.authorZhang, M-
dc.contributor.authorFurusyo, N-
dc.contributor.authorNakamuta, M-
dc.contributor.authorNomura, H-
dc.contributor.authorKajiwara, E-
dc.contributor.authorTsai, PC-
dc.contributor.authorYeh, ML-
dc.contributor.authorAzuma, K-
dc.contributor.authorDohmen, K-
dc.contributor.authorJung, JH-
dc.contributor.authorSong, DS-
dc.contributor.authorKato, M-
dc.contributor.authorKawano, A-
dc.contributor.authorKoyanagi, T-
dc.contributor.authorOoho, A-
dc.contributor.authorSatoh, T-
dc.contributor.authorShimoda, S-
dc.contributor.authorTakahashi, K-
dc.contributor.authorDai, CY-
dc.contributor.authorTran, S-
dc.contributor.authorMaeda, M-
dc.contributor.authorHuang, JF-
dc.contributor.authorXu, Q-
dc.contributor.authorYe, Q-
dc.contributor.authorLi, J-
dc.contributor.authorOkubo, T-
dc.contributor.authorItokawa, N-
dc.contributor.authorJun, MJ-
dc.contributor.authorPan, H-
dc.contributor.authorDang, S-
dc.contributor.authorLi, Z-
dc.contributor.authorRen, W-
dc.contributor.authorZhu, Q-
dc.contributor.authorCheung, R-
dc.contributor.authorNiu, J-
dc.contributor.authorLim, SG-
dc.contributor.authorXie, W-
dc.contributor.authorRen, H-
dc.contributor.authorWu, C-
dc.contributor.authorYuen, RMF-
dc.contributor.authorChuang, WL-
dc.contributor.authorTakaguchi, K-
dc.contributor.authorShang, J-
dc.contributor.authorEguchi, Y-
dc.contributor.authorFukunishi, S-
dc.contributor.authorChuma, M-
dc.contributor.authorTamori, A-
dc.contributor.authorUeno, Y-
dc.contributor.authorHayashi, J-
dc.contributor.authorTanaka, Y-
dc.contributor.authorYu, ML-
dc.contributor.authorNguyen, M-
dc.date.accessioned2021-11-23T09:18:22Z-
dc.date.available2021-11-23T09:18:22Z-
dc.date.issued2021-
dc.identifier.citationThe 30th Annual Conference of the Asian Pacific for The Study of Liver (APASL), Hybrid Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S60-S61-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/308327-
dc.descriptionPoster presentation - Hepatitis C: no. I-26-
dc.description.abstractObjectives: The Western Pacific is a large region but few studies have examined the real-world outcomes of DAAs in a multinational study with diverse HCV genotypes (GT). This REAL-C study (real-world evidence from the Asia Pacific Rim Liver Consortium for HCV) will characterize CHC patients treated with DAAs in routine practice. Methods: We analyzed 11,099 CHC patients from 51 REAL-C clinical sites from Mainland China, Hong Kong, Taiwan, Korea, Japan, and Singapore. The primary outcome was SVR12. Results: The cohort had mean age of 64.0, 44.8% male, 24.2% Chinese (10.0% Mainland China, 1.2% HK, 13.0% Taiwan), 7.5% Korean, 68.1% Japanese, 32.6% with cirrhosis, 9.1% HCC, and 27.0% treatment-experienced (TE: 23.2% interferon, 3.8% DAA). The largest group was GT1 (7837 [70.6%]: 642 1a, 7195 1b), then GT2 (2945 [26.5%]: 1761 2a, 1184 2b), GT3 (211: 70 3a, 126 3b, 11 others), GT6 (91), GT4 (5), and mixed (10). DAA use was also diverse: 3349 (30.2%) SOF/LDF ± RBV, 2437 (22.0%) SOF + RBV, 2251 (20.3%) DCV + ASV, 1270 (11.4%) 2D/3D ± RBV, 633 (5.7%) GLE/PIB, 623 (5.6%) SOF/VEL ± RBV, and others. Overall SVR12 was 96.2% (10,674/11099). By cirrhosis and prior treatment, SVR12 was > 96% for all groups, except GT1 cirrhosis/TE (93.4%, 759/813), GT2 cirrhosis/TE (89.0%, 146/164 [144 with SOF + RBV]), GT3 cirrhosis/TE (88.9%, 8/9), and GT6 no cirrhosis/TE (93.3%, 14/15). There was no treatment-related SAE. Conclusion: In this diverse cohort of Asian patients with genotypes 1, 2, 3, 4 and 6, the overall cure rate was 96.2%, despite large numbers of cirrhosis, HCC, prior treatment failure, and older DAA use.-
dc.languageeng-
dc.publisherSpringer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072-
dc.relation.ispartofHepatology International-
dc.relation.ispartofThe 30th Annual Conference of the Asian Pacific for The Study of Liver (APASL), 2021-
dc.titleTreatment outcome with DAAs in a multinational cohort of 11,099 hepatitis C (CHC) patients with genotypes 1, 2, 3, 4 and 6: A REAL-C study-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.natureabstract-
dc.identifier.hkuros327162-
dc.identifier.volume15-
dc.identifier.issueSuppl. 1-
dc.identifier.spageS60-
dc.identifier.epageS61-
dc.publisher.placeIndia-
dc.identifier.partofdoi10.1007/s12072-021-10213-7-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats